The US Food and Drug Administration (FDA) has given clearance to Defibtech for its Lifeline Pro and Lifeline ECG automated external defibrillators (AEDs).
These external defibrillators feature a revolutionary color LCD video display and 3-lead ECG monitoring capability.
“With the addition of the Lifeline PRO and ECG AEDs, the entire family of Lifeline AEDs is now available in the USA,” said Glenn W Laub, CEO, Defibtech. “There are excellent options for every customer, no matter the budget or the need. With sudden cardiac arrest such a common and foreseeable occurrence, all workplaces and public places should take the reasonable precaution of having at least one AED onsite.”
Both the Lifeline PRO and ECG AEDs are designed for professional responders. The Lifeline PRO provides full manual control over shock energy and delivery as an option. When the Lifeline PRO is operated in manual mode, an ECG appears on the color video display, and the rescuer can select the energy level and decide when to initiate charge and shock.
Operating in semi-automatic or “AED” mode, both the Lifeline PRO and ECG AEDs can display either an ECG or video instructions for the rescuer. In this mode, the AED determines whether or not a shock is warranted through field-proven arrhythmia detection technology. Both models’ video and audio provide guidance on where to place the defibrillating pads and give step-by-step lifesaving instructions.
The company states that both the Lifeline PRO and ECG AEDs are also distinguished by ruggedness and durability, award-winning ergonomic design, and biphasic technology, a clinically proven waveform and algorithm to deliver shocks and save lives.
